Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maraviroc - ViiV Healthcare

Drug Profile

Maraviroc - ViiV Healthcare

Alternative Names: Celsentri; MVC; Selzentry; UK-427857

Latest Information Update: 22 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer; University of California at San Francisco
  • Developer International Partnership for Microbicides; National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA); Pfizer; ViiV Healthcare
  • Class Antiretrovirals; Cyclohexanes; Small molecules; Triazoles
  • Mechanism of Action CCR5 receptor antagonists; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections
  • Phase II COVID 2019 infections
  • No development reported Hypertriglyceridaemia
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 06 Mar 2021 Interim efficacy data from a phase II/III trial in HIV-1 infections presented at the 28th Conference on Retroviruses and Opportunistic Infections (CROI-2021)
  • 06 Mar 2021 University of Hawaii, ViiV Healthcare and University of Puerto Rico completed the phase II/III trial in HIV-1 infections in Hawaii and Puerto Rico (PO) before March 2021 (NCT02159027)
  • 26 Jun 2020 Phase-II clinical trials in COVID-2019 infections (In adults, In the elderly) in Spain (PO) (NCT04441385)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top